LALPATHLAB2024-10-012024-12-31 LALPATHLAB2024-10-012024-12-31 LALPATHLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2024-12-31 LALPATHLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539524 LALPATHLAB NOTLISTED Dr. Lal Path Labs Ltd. Equity 2024-04-01 2025-03-31 2025-01-30 2025-01-23 INR Millions Third quarter 10:00:00 13:32:00 2025-01-30 2025-01-30 Not applicable Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2024-10-01 2024-12-31 Unaudited Consolidated 5967000000.00 251000000.00 6218000000.00 1170000000.00 0.00 0.00 1264000000.00 53000000.00 355000000.00 1993000000.00 4835000000.00 1383000000.00 0.00 1383000000.00 395000000.00 7000000.00 402000000.00 0.00 981000000.00 0.00 0.00 0.00 0.00 981000000.00 -1000000.00 980000000.00 967000000.00 14000000.00 966000000.00 14000000.00 836000000.00 10 11.60 11.58 0.00 0.00 11.60 11.58 i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2024 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ( Ind AS 34 ), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. During the nine months ended 31 December 2024, the Parent Company has issued 15,983 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options. Further, during the nine months ended 31 December 2024, the Parent Company has issued 93,900 equity shares of face value of Rs. 10 each , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 ( ESOP Plan, 2022 ). Due to size constraint, we have not pasted complete notes to statement of financial results. Please refer pdf file for complete notes to the statement of Financial Results for the quarter and nine months ended December 31, 2024. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 18588000000.00 676000000.00 19264000000.00 3637000000.00 0.00 0.00 3670000000.00 173000000.00 1055000000.00 6016000000.00 14551000000.00 4713000000.00 0.00 4713000000.00 1327000000.00 19000000.00 1346000000.00 0.00 3367000000.00 0.00 0.00 0.00 0.00 3367000000.00 -10000000.00 3357000000.00 3323000000.00 44000000.00 3313000000.00 44000000.00 836000000.00 10 39.91 39.83 0.00 0.00 39.91 39.83 Fees to collection centers/channel partners 867000000.00 Other expenses 1126000000.00 Fees to collection centers/channel partners 2641000000.00 Other expenses 3375000000.00 Remeasurement of the defined benefit n obligations 1000000.00 Remeasurement of the defined benefit n obligations -13000000.00 1000000.00 -13000000.00 1000000.00 -2000000.00 Exchange differences on translation of foreign operations -1000000.00 Exchange differences on translation of foreign operations 1000000.00 -1000000.00 1000000.00 0.00 0.00